Introduction

Triple-negative breast cancer (TNBC) accounts for approximately 10%-15% of all diagnosed breast cancers and is associated with an aggressive natural history and poor clinical outcomes. Immunotherapy using immune checkpoint inhibitors has emerged as an effective therapeutic option for TNBC. The results of the IMpassion130 trial have recently led to the approval of the combination of atezolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable locally advanced or metastatic, PD-L1-positive TNBC.

Areas covered

This article summarizes the clinical development and ongoing research on atezolizumab in the treatment of metastatic TNBC. Results of atezolizumab monotherapy trials and data from combination studies with chemotherapy in the advanced setting are reviewed, with special focus on the design, methods, and key findings of the IMpassion130 trial.

Expert opinion

The approval of atezolizumab plus nab-paclitaxel represents an important advance in the treatment of metastatic TNBC. This combination has a favorable risk-benefit profile and is associated with clinically meaningful outcomes. However, further research is needed to identify better predictive biomarkers of response as well as novel immunotherapeutic strategies with atezolizumab and other anticancer drugs.

中文翻译：

---

Atezolizumab在治疗转移性三阴性乳腺癌中的应用。

介绍

三阴性乳腺癌（TNBC）约占所有诊断出的乳腺癌的10％-15％，并伴有侵略性的自然病史和不良的临床预后。使用免疫检查点抑制剂的免疫疗法已成为TNBC的有效治疗选择。IMpassion130试验的结果最近导致批准将atezolizumab和nab-紫杉醇联合用于一线治疗无法切除的局部晚期或转移性PD-L1阳性TNBC患者。

覆盖区域

本文总结了atezolizumab在转移性TNBC治疗中的临床进展和正在进行的研究。回顾了atezolizumab单药试验的结果以及晚期化疗联合研究的数据，特别侧重于IMpassion130试验的设计，方法和关键发现。

专家意见

Atezolizumab加nab-紫杉醇的批准代表了转移性TNBC治疗的重要进展。这种组合具有良好的风险获益特征，并与临床有意义的结果相关。但是，还需要进一步的研究来确定更好的预测性反应生物标志物以及Atezolizumab和其他抗癌药物的新型免疫治疗策略。